123 related articles for article (PubMed ID: 24991313)
21. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
22. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
[TBL] [Abstract][Full Text] [Related]
23. Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis.
Marra CA; Bansback N; Anis AH; Shojania K
Clin Rheumatol; 2011 Mar; 30 Suppl 1():S9-18. PubMed ID: 21359506
[TBL] [Abstract][Full Text] [Related]
24. Impact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid Arthritis.
Costello R; David T; Jani M
Clin Ther; 2019 Jul; 41(7):1376-1396. PubMed ID: 31196653
[TBL] [Abstract][Full Text] [Related]
25. UK-South Asian patients' experiences of and satisfaction toward receiving information about biologics in rheumatoid arthritis.
Kumar K; Raizada SR; Mallen CD; Stack RJ
Patient Prefer Adherence; 2018; 12():489-497. PubMed ID: 29670337
[TBL] [Abstract][Full Text] [Related]
26. Understanding the patient perspective - results of the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) patient needs survey.
McInnes IB; Combe B; Burmester G
Clin Exp Rheumatol; 2013; 31(3):350-7. PubMed ID: 23406685
[TBL] [Abstract][Full Text] [Related]
27. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
28. Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis.
Bansback N; Fu E; Sun H; Guh D; Zhang W; Lacaille D; Milbers K; Anis AH
Curr Rheumatol Rep; 2017 Sep; 19(9):54. PubMed ID: 28752490
[TBL] [Abstract][Full Text] [Related]
29. Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal.
Laires PA; Mesquita R; Veloso L; Martins AP; Cernadas R; Fonseca JE
BMC Musculoskelet Disord; 2013 Sep; 14():279. PubMed ID: 24067096
[TBL] [Abstract][Full Text] [Related]
30. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
[TBL] [Abstract][Full Text] [Related]
31. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
[TBL] [Abstract][Full Text] [Related]
32. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
Barton P; Jobanputra P; Wilson J; Bryan S; Burls A
Health Technol Assess; 2004 Mar; 8(11):iii, 1-91. PubMed ID: 14982655
[TBL] [Abstract][Full Text] [Related]
33. PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH.
Moloney R; Mohr P; Hawe E; Shah K; Garau M; Towse A
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):90-8. PubMed ID: 26168804
[TBL] [Abstract][Full Text] [Related]
34. Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis.
Mukherjee K; Kamal KM
Am Health Drug Benefits; 2017 Feb; 10(1):7-15. PubMed ID: 28465764
[TBL] [Abstract][Full Text] [Related]
35. Barriers From Third-Party Payers to Biologic Use in Pediatric Inflammatory Bowel Disease.
Lepus CA; Hyams JS
JPGN Rep; 2022 Aug; 3(3):e215. PubMed ID: 37168642
[TBL] [Abstract][Full Text] [Related]
36. Biologics Prescribing for Rheumatoid Arthritis in Older Patients: A Single-Center Retrospective Cross-Sectional Study.
Morsley K; Kilner T; Steuer A
Rheumatol Ther; 2015 Dec; 2(2):165-172. PubMed ID: 27747537
[TBL] [Abstract][Full Text] [Related]
37. Beyond the cost of biologics: employer survey reveals gap in understanding role of specialty pharmacy and benefit design.
Vogenberg FR; Larson C; Rehayem M; Boress L
Am Health Drug Benefits; 2012 Jan; 5(1):23-30. PubMed ID: 24991308
[TBL] [Abstract][Full Text] [Related]
38. Creating value-focused healthcare delivery systems: Part three--Core competencies.
Beveridge RN
J Oncol Manag; 1997; 6(6):16-23. PubMed ID: 10174597
[TBL] [Abstract][Full Text] [Related]
39. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
